- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05733416
Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO)
October 30, 2023 updated by: Ottawa Hospital Research Institute
Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Recruiting
- The Ottawa Hospital
-
Contact:
- Michele Demetroff
- Phone Number: 6137985555
- Email: mdemetrof@ohri.ca
-
Principal Investigator:
- Dar Dowlatshahi, MD PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- adults ≥18 years
- presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
- patient or delegate willing and able to provide informed consent.
Exclusion Criteria:
- contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
- active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive Cancer Screening
Usual care plus PDG PET/CT
|
F-fluorodeoxyglucose positron emission/computed tomography
|
Other: Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
|
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Recruitment
Time Frame: Over 12 months
|
Number of participants recruited
|
Over 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eligibility Rate
Time Frame: Over 12 months
|
proportion of screened patients who are eligible
|
Over 12 months
|
Consent Rate
Time Frame: Over 12 months
|
proportion of eligible patients who provide consent
|
Over 12 months
|
Retention Rate
Time Frame: Over 24 months
|
proportion of participants retained at follow-up
|
Over 24 months
|
Study Completion Rate
Time Frame: Over 24 months
|
proportion of participants who completed all study procedures
|
Over 24 months
|
Adherence Rate
Time Frame: Over 24 months
|
adherence to screening strategy
|
Over 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Screening time frame
Time Frame: Over 24 months
|
time from diagnosis to screening
|
Over 24 months
|
Reasons for participation
Time Frame: Over 24 months
|
Reasons for accepting/declining participation
|
Over 24 months
|
Usual care cancer screening strategies
Time Frame: Over 24 months
|
Usual care cancer screening strategies ordered by treating physicians
|
Over 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
January 28, 2023
First Submitted That Met QC Criteria
February 8, 2023
First Posted (Actual)
February 17, 2023
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20230006-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Occult Cancer
-
National Institute of Gastroenterology, CubaUnknownColonoscopy | Occult Blood | Immunologic TestsCuba
-
Ezra CohenSignalRX Pharmaceuticals, Inc.TerminatedMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaUnited States
-
Hadassah Medical OrganizationCompleted
-
European Institute of OncologyRecruitingBreast Cancer | Occult Breast CarcinomaItaly
-
Norman A. ParadisUnited States Department of Defense; Dartmouth College; University of Maryland...Not yet recruitingHemorrhage | Occult BleedingUnited States
-
US Department of Veterans AffairsTerminatedOccult GI BleedingUnited States
-
Aga Khan University Hospital, PakistanCompletedBreast Cancer | Genetic Predisposition | BRCA Mutation | Occult CancerPakistan
-
Dartmouth-Hitchcock Medical CenterUnited States Department of Defense; Ohio State University; Dartmouth CollegeTerminatedHemorrhage | Hemorrhagic Shock | Occult BleedingUnited States
-
Hebei Medical University Third HospitalUnknownHumeral Greater Tuberosity | Humeral Fractures/ Proximal | Fractures/ OccultChina
-
Rabin Medical CenterUnknown
Clinical Trials on FDG PET/CT
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Region VästerbottenUmeå UniversityRecruitingCervix Cancer | Endometrial Cancer | Epithelial Ovarian CancerSweden
-
Jewish General HospitalRecruitingVasculitis | Giant Cell ArteritisCanada
-
Institute of Oncology LjubljanaUniversity of LjubljanaUnknownCorrelation of iRADIOMICS and irRC With SurvivalSlovenia
-
Centre Hospitalier Universitaire Saint PierreCompletedExtrapulmonary Tuberculosis in HIV Patients
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
University of ZurichWithdrawnAdenocarcinoma | Stomach Cancer | Cancer of Esophagogastric JunctionSwitzerland